Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28823607 | 0.87 | HTR2A (0.47) | HTR2AFFAR4GABRA1GABRB1PKM | |
| SCHEMBL14818404 | 0.85 | HTR2A (0.48) | HTR2AFFAR4GABRA1GABRB1PKM | |
| SCHEMBL17449704 | 0.78 | HTR2A (0.50) | HTR2AFFAR4PKMNPSR1CTSA | |
| SCHEMBL18768202 | 0.77 | HTR2A (0.52) | HTR2AFFAR4PKMNPSR1DHFR | |
| SCHEMBL1007650 | 0.76 | HTR2A (0.55) | HTR2AFFAR4PKMNPSR1DHFR | |
| SCHEMBL4750485 | 0.76 | HTR2A (0.51) | HTR2AFFAR4PKMNPSR1 | |
| SCHEMBL1005341 | 0.76 | HTR2A (0.51) | HTR2AFFAR4PKMNPSR1DHFR | |
| SCHEMBL16111306 | 0.75 | HTR2A (0.55) | HTR2AFFAR4PKMNPSR1CTSA | |
| SCHEMBL2439246 | 0.73 | HTR2A (0.52) | HTR2AFFAR4PKMNPSR1CTSA | |
| SCHEMBL16483443 | 0.73 | HTR2A (0.52) | HTR2AFFAR4PKMNPSR1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906542-B1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015125786-A1 | AMINOPYRAZOLONE DERIVATIVE | 第一三共株式会社 | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR180, GPR88 | HTR2A 424/4885FFAR4 27/4885GABRA1 491/4885 |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | HTR2A 3841/4885FFAR4 3786/4885GABRA1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.